Clinical Trial Update: EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

View source ↗

Summary

Clinical trial update exploring EVER/TMC mutation as a marker of the risk of skin cancer in immunosuppressed patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Cancer

Snippet

Sponsor: Andreas Arnold | Conditions: Immunosuppression, Neoplasm | Status: COMPLETED